Do waiting times really matter?

Por Brown, Melissa M
Publicado em 2007

Outcome of corneal transplantation

Por Brown, Melissa M, Brown, Gary C
Publicado em 2002

Quality of life and systemic comorbidities in patients with ophthalmic disease

Por Brown, Melissa M, Brown, Gary C, Sharma, Sanjay, Hollands, Hussein, Landy, Jennifer
Publicado em 2002

THE GOAL OF VALUE-BASED MEDICINE ANALYSES: COMPARABILITY. THE CASE FOR NEOVASCULAR MACULAR DEGENERATION

Por Brown, Gary C., Brown, Melissa M., Brown, Heidi C., Kindermann, Sylvia, Sharma, Sanjay
Publicado em 2007

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Por Brown, Gary C., Brown, Melissa M., Lieske, Heidi B., Turpcu, Adam, Rajput, Yamina
Publicado no Int J Retina Vitreous (2017)

A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

Por Brown, Gary C., Brown, Melissa M., Lieske, Heidi B., Lieske, Philip A., Brown, Kathryn S.
Publicado no Int J Retina Vitreous (2015)

Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Por Olk, R. Joseph, Peralta, Enrique, Gierhart, Dennis L., Brown, Gary C., Brown, Melissa M.
Publicado no Int J Retina Vitreous (2015)

Service Utilization of Veterans Dually Eligible for VA and Medicare Fee-For-Service: 1999–2004

Por Humensky, Jennifer, Carretta, Henry, de Groot, Kristin, Brown, Melissa M., Tarlov, Elizabeth, Hynes, Denise M.
Publicado em 2012

VALUE-BASED MEDICINE AND OPHTHALMOLOGY: AN APPRAISAL OF COST-UTILITY ANALYSES

Por Brown, Gary C, Brown, Melissa M, Sharma, Sanjay, Brown, Heidi, Smithen, Lindsay, Leeser, David B, Beauchamp, George
Publicado em 2004

THE BURDEN OF AGE-RELATED MACULAR DEGENERATION: A VALUE-BASED MEDICINE ANALYSIS

Por Brown, Gary C, Brown, Melissa M, Sharma, Sanjay, Stein, Joshua D, Roth, Zachary, Campanella, Joseph, Beauchamp, George R
Publicado em 2005